Literature DB >> 22639052

Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.

Dariusz Zakrzewski1, Ilona Seferynska, Krzysztof Warzocha, Tomasz Hryniewiecki.   

Abstract

We present the case of a 72-year-old male with chronic phase myeloid leukemia. Elevation of the pulmonary artery pressure due to nilotinib therapy was noted. This effect on pulmonary artery pressure was nilotinib dose dependent.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22639052     DOI： 10.1007/s12185-012-1103-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  11 in total

1.  Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.

Authors:  D Mattei; M Feola; F Orzan; N Mordini; D Rapezzi; A Gallamini
Journal:  Bone Marrow Transplant       Date:  2008-12-22       Impact factor: 5.483

2.  Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.

Authors:  Yvonne Will; James A Dykens; Sashi Nadanaciva; Brad Hirakawa; Joseph Jamieson; Lisa D Marroquin; James Hynes; Shem Patyna; Bart A Jessen
Journal:  Toxicol Sci       Date:  2008-07-29       Impact factor: 4.849

3.  Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.

Authors:  Walid Rasheed; Brendan Flaim; John F Seymour
Journal:  Leuk Res       Date:  2008-11-04       Impact factor: 3.156

4.  Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.

Authors:  Ester M Orlandi; Barbara Rocca; Anna S Pazzano; Stefano Ghio
Journal:  Leuk Res       Date:  2011-09-03       Impact factor: 3.156

5.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.

Authors:  Mark H Williams; Clive E Handler; Raza Akram; Colette J Smith; Clare Das; Joanna Smee; Devaki Nair; Christopher P Denton; Carol M Black; John G Coghlan
Journal:  Eur Heart J       Date:  2006-04-27       Impact factor: 29.983

6.  Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.

Authors:  Hossein A Ghofrani; Nicholas W Morrell; Marius M Hoeper; Horst Olschewski; Andrew J Peacock; Robyn J Barst; Shelley Shapiro; Heiko Golpon; Mark Toshner; Friedrich Grimminger; Steve Pascoe
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

7.  An evaluation of the cardiotoxicity of imatinib mesylate.

Authors:  Antonio Luiz Ribeiro; Milena Soriano Marcolino; Henrique N S Bittencourt; Márcia M Barbosa; Maria do Carmo P Nunes; Vitor Fonseca Xavier; Nelma C D Clementino
Journal:  Leuk Res       Date:  2008-05-20       Impact factor: 3.156

8.  Congestive heart failure is a rare event in patients receiving imatinib therapy.

Authors:  Ehab Atallah; Jean-Bernard Durand; Hagop Kantarjian; Jorge Cortes
Journal:  Blood       Date:  2007-04-20       Impact factor: 22.113

9.  Preclinical evaluation of potential nilotinib cardiotoxicity.

Authors:  Armin Wolf; Philippe Couttet; Min Dong; Olivier Grenet; Marcia Heron; Ursula Junker; David Ledieu; Andreas Mahl; Estelle Marrer; Elke Persohn; Francois Pognan; Wei Zhou; Jeffrey Tsao; Danielle Roman
Journal:  Leuk Res       Date:  2010-12-03       Impact factor: 3.156

10.  Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?

Authors:  Jan K Hennigs; Gunhild Keller; Hans Jörg Baumann; Friedemann Honecker; Stefan Kluge; Carsten Bokemeyer; Tim H Brümmendorf; Hans Klose
Journal:  BMC Pulm Med       Date:  2011-05-23       Impact factor: 3.317
View more
  3 in total

Review 1.  Dasatinib-induced pulmonary arterial hypertension.

Authors:  Nurgül Özgür Yurttaş; Ahmet Emre Eşkazan
Journal:  Br J Clin Pharmacol       Date:  2018-03-06       Impact factor: 4.335

2.  Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase.

Authors:  Ibuki Takatsuka; Hiroya Hirata; Takumi Takahashi; Satoshi Dohtan; Shinichiro Oka; Nami Sakamoto; Masamitsu Takaba; Miwa Adachi; Tomonari Takemura; Yasuyuki Nagata; Takaaki Ono
Journal:  Leuk Res Rep       Date:  2022-04-19

Review 3.  Differentiating pulmonary hypertension associated with protein kinase inhibitors.

Authors:  Joshua A Jacobs; Eiman Jahangir; John J Ryan
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.